4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
CARsgen Therapeutics Holdings Limited (2171) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 355 employees. Its market capitalization is roughly CNY 9 billion. In the fiscal year ended 2025-12-31, 2171 reported CNY 126M in revenue and (CNY 98M) in net income.
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | CNY 126M | CNY 39M | CNY 0M | CNY 0M |
| Gross Profit | CNY 80M | CNY 15M | CNY 0M | CNY 0M |
| Operating Income (EBIT) | (CNY 228M) | (CNY 574M) | (CNY 785M) | (CNY 802M) |
| Net Income | (CNY 98M) | (CNY 798M) | (CNY 748M) | (CNY 892M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 1.3B | CNY 1.7B | CNY 2.3B | CNY 2.8B | — |
| Total Liabilities | CNY 513M | CNY 616M | CNY 456M | CNY 290M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2171 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms